US Patent 8,129,342 (Daptomycin Aggregate/Micelle Process and Purity): Scope, Claim Architecture, and Landscape

US Drug Patent 8,129,342 is centered on a defined daptomycin purity spec measured by HPLC and a specific manufacturing pathway that forms a daptomycin aggregate (including micelles) and then isolates daptomycin from that aggregate. The claims tie the end product (composition and pharmaceutical formulations) to tightly bounded impurity profiles including impurities 1-14 (defined by peaks 1-14 in FIG. 12), plus explicit caps on anhydro-daptomycin, β-isomer, and lactone hydrolysis product.

Below is a structured breakdown of claim scope, claim-strength drivers, infringement sensitivity, and how the patent fits into a broader daptomycin purification and formulation landscape.

What is the core claimed invention?

Purity definition (the claim anchor)

The dominant restriction across compositions and pharma formulations is:

“daptomycin of greater than or about 93% purity relative to impurities 1-14 defined by peaks 1-14 shown in FIG. 12”
plus optional or dependent impurity caps:
- < 4% anhydro-daptomycin (dependent claims)
- < 4% β-isomer (dependent claims)
- < 1% lactone hydrolysis product (dependent claims)

This purity framework appears in:

independent claim 1
independent claim 17 (pharmaceutical composition tied to claim 1 purity)
independent claim 30 (composition purified by micelles with >93% purity)
independent claim 40 (pharma solution tied to micelle purification and >93% purity)
independent claim 51 and related lyophilized powder/vial claims (50, 53, 54)

Manufacturing definition (process that must generate aggregate/micelle)

Multiple claims require a process step of:

forming a “daptomycin aggregate”
in key embodiments, the aggregate is described as:
- a daptomycin micelle (claims 22, 30, 31, 40, 51)
- an aggregate that is retained on a filter (claims 5, 23)
- followed by collection and optionally lyophilization (claims 6, 15, 50)

Claim 5 gives a full method outline that is likely the most infringement-sensitive process claim:

provide daptomycin solution in monomeric and nonmicellar state
filter under conditions that allow daptomycin passage while excluding pyrogens
induce aggregate formation
filter aggregate so the aggregate is retained on the filter
collect aggregate
(claim 5 text in the prompt)

This is later supplemented by additional purification steps in dependent claims:

anion exchange chromatography (claim 22)
hydrophobic interaction chromatography (claims 24, also via “one or more steps selected from” in claims 50-51)

How do the claims map into scopes of protection?

1) Composition claims (product-by-process, purity-anchored)

Claim 1: a composition made by forming a daptomycin aggregate, with:

>≈93% purity vs impurities 1-14 (FIG. 12 peaks)
<4% anhydro-daptomycin
<4% β-isomer

Claims 2-4 add impurity elimination/measurement features:

claim 2: composition is free of impurities 1-14
claim 3: essentially free of at least one impurity 1-14
claim 4: purity measured by HPLC

Claims 7-14 narrow impurity/purity levels:

claim 7: <1% β-isomer
claim 8: >93% purity
claim 9: <1% lactone hydrolysis product
claim 10: substantially free of β-isomer
claim 11: (>93% purity) + essentially free of β-isomer
claim 12: ≥95% purity
claim 13: about 94 to 96% purity
claim 14: ≥97% purity

Claims 15-16: lyophilized daptomycin composition with stronger impurity constraints:

93% purity (impurities 1-14 by FIG. 12)
<1% lactone hydrolysis product
claim 16: essentially free of β-isomer

Claims 51-53 broaden to aggregate-to-monomers-to-isolation with chromatographic steps:

claim 51: composition produced by:
- forming daptomycin aggregate
- converting aggregate to monomers
- obtaining daptomycin from monomers using chromatography selected from:
- anion exchange chromatography
- hydrophobic interaction chromatography
with >≈93% purity vs impurities 1-14 (FIG. 12)
claim 53: lyophilized powder compatible with carrier for 1-12 mg/kg daily IV, with:
- purity about 94 to 96%
- <1% lactone hydrolysis product
- <4% anhydro-daptomycin
- <4% β-isomer

Claim 52: derivative narrowing to >93% purity vs impurities 1-14.

Key scope feature: multiple claims are “composition obtained by process” with a purity spec that operates as a product boundary, so even if process details vary, the resulting impurity profile and method-defined starting point can remain within scope.

2) Pharmaceutical composition claims (formulation + infection indications + dosing)

Claim 17: pharmaceutical composition with pharmaceutically acceptable carrier for infection of:

blood, skin, or soft tissue using daptomycin obtained by forming aggregate and with >≈93% purity vs FIG. 12 impurities.

Claims 18-21 add:

claim 18: >93% purity + <4% anhydro daptomycin
claim 19: carrier reconstitution options:
- physiological saline
- Ringer’s solution
claim 20: daily dose 1 to 12 mg/kg in reconstituted solution
claim 21: integrated limitation:
- (a) carrier saline/Ringer’s
- (b) daptomycin has:
- 93% purity
- <4% anhydro daptomycin
- <4% β-isomer
- (c) composition obtained by purification process including aggregate formation and obtaining daptomycin from aggregate

Claims 22-24 add purification pathway details:

claim 22:
- anion exchange chromatography to enrich daptomycin preparation
- form daptomycin aggregate comprising daptomycin micelle in enriched prep or derived composition
- obtain daptomycin from aggregate
claim 23:
- filtering aggregate where aggregate retained on filter; collect aggregate
claim 24:
- further hydrophobic interaction chromatography to obtain semi-purified prep; obtain daptomycin

Claims 25-29 specify infection pathogens:

claim 25: S. aureus
claim 26: bacteremia
claim 27: endocarditis
claim 28: skin/soft tissue infection
claim 29: includes bacteria selected from:
- S. aureus
- S. pyogenes
- S. agalactiae
- Enterococcus faecalis

Claim 30-39 is a parallel track, but purity + “micelles comprising daptomycin” appears as the purification process basis:

claim 30: pharmaceutical composition for treatment of infection with:
- 93% purity vs impurities 1-14 by FIG. 12
- purified by process comprising formation of micelles comprising daptomycin
claims 31-34: lyophilized powder and tighter impurity caps (anhydro <4%, lactone hydrolysis <1%, essentially β-free)
claims 35-39: pathogen/indication subsets identical in pattern to 25-29

Claim 40-49 is a second formulation track:

claim 40: IV administration composition with carrier solution and daptomycin:
- 93% purity vs FIG. 12 impurities
- daptomycin obtained from purification process comprising formation of daptomycin micelle
claims 41-43: impurity limits (anhydro <4%, lactone hydrolysis <1%, essentially β-free)
claims 44-48: pathogen/indication subsets identical in pattern to 25-29
claim 49: daily IV dose 1 to 12 mg/kg

Claim 50 focuses on the vial format:

lyophilized powder compatible with carrier for daily IV dose
daptomycin has >≈93% purity
process includes:
- forming daptomycin aggregate
- converting aggregate to monomers
- obtaining from monomers using chromatography selected from:
- anion exchange chromatography
- hydrophobic interaction chromatography

Claim 54 specifies multiple infections and dosing for the lyophilized powder:

infections of blood, skin, and/or soft tissue
daily IV dose 1-12 mg/kg

Which claims are most likely to be enforceable in practice?

Highest enforcement leverage: purity + aggregate/micelle + isolation

From a manufacturing infringement perspective, the strongest combination is: 1) Aggregate/micelle formation required 2) Isolation from the aggregate (filter retention or collection; or aggregate to monomers then chromatographic isolation) 3) Tight impurity profile tied to FIG. 12 peaks

That points to independent claims:

1 (aggregate formation + purity vs FIG. 12 impurities + caps)
17 (pharmaceutical composition version)
30 (micelle purification version)
40 (IV solution version)
51 (aggregate-to-monomers-to-chromatography version)

Process-only sensitivity: filter/pyrogen exclusion and aggregate retention

Claim 5 is the most operationally specific method claim:

monomeric and nonmicellar starting state
pyrogen-excluding pre-filter that allows daptomycin passage
aggregate induction
retention of aggregate on filter and collecting aggregate
This claim narrows scope to a particular unit-operation sequence.

If a manufacturer uses a different isolation mechanism (for example, precipitation or membrane fractionation), claim 5 may be avoided even if the final product purity is within bounds. Claims 1/17/30/40/51, though, can still capture the product if the process still qualifies as forming aggregates/micelles and isolating accordingly.

How broad is the scope around impurity limits?

Impurities 1-14 (FIG. 12) are the metes and bounds

Instead of generic “impurities,” the claims reference:

impurities 1-14 defined by peaks 1-14 in FIG. 12
with purity measured against those impurities

This is a strong claim characterization tool because it:

forces a defined analytical framework
anchors the “purity” calculation to specific chromatographic peaks

Secondary caps refine the boundary

The claims repeatedly impose:

anhydro-daptomycin <4%
β-isomer <4% (and in dependent claims <1%; “essentially free”)
lactone hydrolysis product <1%

These caps appear across multiple independent-to-dependent chains, including lyophilized products and IV formulations.

What does the claim architecture imply for design-around?

Likely design-around vectors

Avoid qualifying “aggregate/micelle formation” as a defined process step. If the purification does not involve aggregation/micellization of daptomycin as claimed, infringement risk drops for claims requiring that step.
Change isolation mechanism such that aggregate is not retained on a filter as specified in claim 5/23.
Shift impurity profile outside the defined caps for anhydro-daptomycin, β-isomer, or lactone hydrolysis product.
Use chromatography that is not within the “selected from” list in claims 50-51 (anion exchange and hydrophobic interaction). Note claim 50-51 explicitly list those two; claims still might capture other chromatography if it is used in addition, but pure “selected from” limits create an argument pathway.

Limitations that also reduce freedom

Multiple claims repeatedly bring you back to:
- product-by-process language
- 93% purity relative to FIG. 12 impurities
- caps on specific degradation/isomerization impurities

In practice, product spec alignment is harder to change than process selection.

Patent landscape: where US 8,129,342 sits relative to likely daptomycin process and purity patents

Without live bibliographic access here, the landscape can still be mapped at the claim-theme level, using what the patent itself discloses as “technical axes.” The market implication is how competing manufacturers can or cannot credibly avoid these axes.

Landscape axes reflected in the claims

1) Daptomycin aggregate/micelle-mediated purification

Claims 1, 5, 17, 22, 23, 30, 40, 50, 51 2) Chromatographic finishing anchored to aggregate-to-monomer conversion
Claims 22, 24, 50, 51 3) Tight HPLC impurity spec tied to a defined chromatogram figure
Claims 1, 4, 8-14, 15, 30, 32-34, 40, 41-43, 50-54 4) Control of specific impurity classes
anhydro-daptomycin (<4%)
β-isomer (<4% or <1%)
lactone hydrolysis product (<1%) 5) Formulation and dosing envelope
IV daily dose 1-12 mg/kg
carrier is physiological saline or Ringer’s solution
lyophilized vial architecture

Competitive positioning

If other patents focus on broad daptomycin purification without aggregate/micelle steps: those may not reach claims 1/5/30/40/51.
If other patents focus on impurity control but use different purification physics: they may be challenged by claim 1’s “process comprising forming a daptomycin aggregate” requirement, depending on how aggregation happens in their process.
If biospec or generic entrants are able to produce a daptomycin drug substance with purity and impurity caps while not using the claimed aggregate/micelle steps, the scope impact shifts toward enforcement difficulty.

In other words, this patent most strongly blocks competitors whose process relies on daptomycin aggregation/micellization as a purification lever and then isolates daptomycin from that state.

Detailed claim table (scope checklist)

Composition claims (product scope)

Claim(s)	Product format	Purity requirement	Additional impurity limits
1	Composition	>≈93% purity vs impurities 1-14 (FIG. 12)	<4% anhydro-daptomycin; <4% β-isomer
2-3	Composition	Based on claim 1 purity	free of impurities 1-14 (claim 2) or essentially free of at least one (claim 3)
4	Composition	Purity measured by HPLC	Analytical method limitation
7,10,16	Composition	based on claim 1	β-isomer <1% or essentially free
8,12-14	Composition	>93%, ≥95%, ~94-96%, or ≥97%	Tied to FIG. 12-based purity
9,15	Composition	based on claim 1	lactone hydrolysis product <1%
51-52,53	Composition / lyophilized powder	>≈93% or ~94-96% purity vs FIG. 12	lactone <1%; anhydro <4%; β-isomer <4% (claim 53)

Pharmaceutical claims (patient-facing scope)

Claim(s)	Administration / format	Indication scope	Dosing / carrier limits	Purity tie-in
17	Pharma with carrier	blood/skin/soft tissue	carrier not yet restricted	daptomycin made by forming aggregate + >≈93% purity vs FIG. 12
19-21	Reconstituted IV solution	blood/skin/soft tissue	saline/Ringer’s; 1-12 mg/kg/day	includes caps (anhydro <4%; β-isomer <4%)
22-24	Pharma with purification steps	blood/skin/soft tissue	(includes chromatography steps)	via aggregate/micelle + isolation
25-29	Pharma	S. aureus, bacteremia, endocarditis, skin/soft tissue	N/A	inherits claim 17/30/40 purity
30-34	Pharma	infection treatment	N/A (beyond inherited)	micelle purification + >93% purity; lyophilized variant
40-43,49	IV composition	blood/skin/soft tissue	saline/Ringer’s implied; daily IV 1-12 mg/kg	micelle purification + purity and impurity caps
50,53-54	Vial / lyophilized powder	infections of blood, skin, soft tissue	1-12 mg/kg/day reconstituted	aggregate-to-monomer-to-chromatography + purity/impurity caps

What claim elements are likely to matter in an invalidity or construction fight?

Key interpretive anchors

“impurities 1-14 defined by peaks 1-14 shown in FIG. 12”
“greater than or about 93% purity relative to impurities 1-14”
“substantially free” / “essentially free” (terms used in dependent claims)
“anhydro-daptomycin,” “β-isomer of daptomycin,” “lactone hydrolysis product”
“daptomycin aggregate” vs “daptomycin micelle”
process sequence tied to monomeric/nonmicellar starting state and aggregate induction

Where validity pressure usually concentrates (based on claim structure)

If prior art shows daptomycin aggregation/micellization in purification and then chromatography, claim novelty may narrow to:
- the particular impurity profile (FIG. 12-based impurities 1-14)
- the specific impurity thresholds (<4%, <1%)
- the specific process sequence and isolation mechanics (filter retention; aggregate to monomers)

Key Takeaways

US 8,129,342 is an aggregate/micelle-mediated daptomycin purification patent anchored on HPLC purity measured against impurities 1-14 (FIG. 12) and capped impurities: anhydro-daptomycin (<4%), β-isomer (<4% or <1%), and lactone hydrolysis product (<1%).
The strongest infringement hooks are process-to-product claims requiring:
- forming a daptomycin aggregate/micelle
- isolating daptomycin from that state (filter retention and collection, or aggregate to monomers then chromatography)
- meeting the FIG. 12 purity and impurity thresholds.
Patient-facing claim scope covers IV daily dosing 1 to 12 mg/kg, carrier reconstitution with physiological saline or Ringer’s solution, and standard infection subsets (blood/skin/soft tissue; pathogens including S. aureus, plus streptococci and Enterococcus faecalis).
Landscape positioning: the patent most directly targets competitors using aggregation/micelle purification as a core purification step coupled with tight chromatographic impurity control tied to a specific figure-based impurity set.

FAQs

1) Does US 8,129,342 protect only lyophilized products?

No. It covers multiple pharmaceutical formats, including compositions with carriers and IV reconstituted solutions, plus a vial/lyophilized powder set of dependent claims (notably claim 50 and lyophilized formulations in claims 15 and 31-34 and 53-54).

2) Is the purity definition based on generic “impurities,” or a specific chromatogram?

It is tied to specific impurities 1-14 defined by peaks 1-14 shown in FIG. 12, and purity is stated as a comparison against those peaks.

3) Are micelle formation and aggregate formation treated as interchangeable in the claims?

The claims treat them closely. Several independent formulations require “aggregate” (claim 1) while parallel branches explicitly require micelles comprising daptomycin (claim 30 and claim 40). Dependent claims link enriched preparations to micelle-containing aggregates.

4) What is the tightest impurity control in the claim set?

The strongest explicit caps are:

β-isomer <1% (claims 7, 10/11 variants, and lyophilized embodiments)
lactone hydrolysis product <1% (claims 9 and 15/32/34/42/43/53)
anhydro-daptomycin <4% appears as a recurring cap, often with β-isomer limits.

5) If a competitor uses anion exchange and hydrophobic interaction chromatography, are they automatically in scope?

Not automatically. Claims 50 and 51 include chromatography as part of a sequence that starts with forming a daptomycin aggregate and converting to monomers. The aggregate/micelle formation step and the FIG. 12 purity/impurity caps are central to the claimed scope.

References

[1] User-provided claim text for US Drug Patent 8,129,342 (claims 1-54 as included in the prompt).

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	311405	⤷ Start Trial
Austria	449785	⤷ Start Trial
Australia	3097801	⤷ Start Trial
Australia	784937	⤷ Start Trial
Brazil	0107731	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,129,342

Summary for Patent: 8,129,342